Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus.

Syed GH, Siddiqui A.

Hepatology. 2011 Dec;54(6):1936-46. doi: 10.1002/hep.24619.

2.

Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus.

Soto-Acosta R, Bautista-Carbajal P, Syed GH, Siddiqui A, Del Angel RM.

Antiviral Res. 2014 Sep;109:132-40. doi: 10.1016/j.antiviral.2014.07.002. Epub 2014 Jul 11.

PMID:
25017471
3.

Antiviral Activity of Nordihydroguaiaretic Acid and Its Derivative Tetra-O-Methyl Nordihydroguaiaretic Acid against West Nile Virus and Zika Virus.

Merino-Ramos T, Jiménez de Oya N, Saiz JC, Martín-Acebes MA.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00376-17. doi: 10.1128/AAC.00376-17. Print 2017 Aug.

4.

Hepatitis C virus hijacks host lipid metabolism.

Syed GH, Amako Y, Siddiqui A.

Trends Endocrinol Metab. 2010 Jan;21(1):33-40. doi: 10.1016/j.tem.2009.07.005. Epub 2009 Oct 23. Review.

5.

Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.

Shahidi M, Tay ES, Read SA, Ramezani-Moghadam M, Chayama K, George J, Douglas MW.

J Gen Virol. 2014 Nov;95(Pt 11):2468-79. doi: 10.1099/vir.0.067231-0. Epub 2014 Jul 22.

PMID:
25053565
6.

Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents.

Olmstead AD, Knecht W, Lazarov I, Dixit SB, Jean F.

PLoS Pathog. 2012 Jan;8(1):e1002468. doi: 10.1371/journal.ppat.1002468. Epub 2012 Jan 5.

7.

Cellular lipid droplets and hepatitis C virus life cycle.

Fukasawa M.

Biol Pharm Bull. 2010;33(3):355-9. Review.

8.

Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production.

Nourbakhsh M, Douglas DN, Pu CH, Lewis JT, Kawahara T, Lisboa LF, Wei E, Asthana S, Quiroga AD, Law LM, Chen C, Addison WR, Nelson R, Houghton M, Lehner R, Kneteman NM.

J Hepatol. 2013 Aug;59(2):336-43. doi: 10.1016/j.jhep.2013.03.022. Epub 2013 Mar 28.

PMID:
23542347
9.

Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus.

Rodgers MA, Villareal VA, Schaefer EA, Peng LF, Corey KE, Chung RT, Yang PL.

J Am Chem Soc. 2012 Apr 25;134(16):6896-9. doi: 10.1021/ja207391q. Epub 2012 Apr 11.

10.

HCV and host lipids: an intimate connection.

Schaefer EA, Chung RT.

Semin Liver Dis. 2013 Nov;33(4):358-68. doi: 10.1055/s-0033-1358524. Epub 2013 Nov 12. Review.

PMID:
24222093
11.

SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes.

Li X, Li Y, Yang W, Xiao C, Fu S, Deng Q, Ding H, Wang Z, Liu G, Li X.

J Steroid Biochem Mol Biol. 2014 Sep;143:174-82. doi: 10.1016/j.jsbmb.2014.02.009. Epub 2014 Feb 22.

PMID:
24565561
12.

Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.

Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A.

PLoS One. 2014 Mar 19;9(3):e92140. doi: 10.1371/journal.pone.0092140. eCollection 2014.

13.

Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.

Saito K, Shirasago Y, Suzuki T, Aizaki H, Hanada K, Wakita T, Nishijima M, Fukasawa M.

J Virol. 2015 Feb;89(4):2220-32. doi: 10.1128/JVI.03385-14. Epub 2014 Dec 3.

14.

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.

Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K.

Hepatology. 2012 Mar;55(3):720-9. doi: 10.1002/hep.24803.

PMID:
22105803
15.

Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression.

Amako Y, Munakata T, Kohara M, Siddiqui A, Peers C, Harris M.

J Virol. 2015 Apr;89(8):4092-101. doi: 10.1128/JVI.01653-14. Epub 2015 Feb 11.

16.

Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies.

Blaising J, Pécheur EI.

Biochimie. 2013 Jan;95(1):96-102. doi: 10.1016/j.biochi.2012.07.016. Epub 2012 Aug 1. Review.

PMID:
22884392
17.

[Roles of lipid droplets in hepatitis C virus life cycle].

Yang XJ, Zhang LL.

Bing Du Xue Bao. 2014 Jan;30(1):91-7. Review. Chinese.

PMID:
24772905
18.

Mulberry extract inhibits oleic acid-induced lipid accumulation via reduction of lipogenesis and promotion of hepatic lipid clearance.

Ou TT, Hsu MJ, Chan KC, Huang CN, Ho HH, Wang CJ.

J Sci Food Agric. 2011 Dec;91(15):2740-8. doi: 10.1002/jsfa.4489. Epub 2011 Oct 17.

PMID:
22002411
19.

[Inhibition of silent information regulator-1 in hepatocytes induces lipid metabolism disorders and enhances hepatitis C virus replication].

Sun LJ, Zhao YH, Li SC, Yu JW, Kang P, Liu W.

Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):834-9. doi: 10.3760/cma.j.issn.1007-3418.2013.11.009. Chinese.

PMID:
24331693
20.

Hepatitis C virus and lipid droplets: finding a niche.

Filipe A, McLauchlan J.

Trends Mol Med. 2015 Jan;21(1):34-42. doi: 10.1016/j.molmed.2014.11.003. Epub 2014 Nov 20. Review.

PMID:
25496657

Supplemental Content

Support Center